Stock Ratings / Health Care / BDSX / forecast

TLSI (34) XGN (31) YDES (37) BNR (23) ⌘ Pro Terminal →

Biodesix Inc. (BDSX) 12-Month Stock Forecast & Price Target Cone

$24.72 +8.14% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $25.04

Biodesix Inc. (BDSX) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $260.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $25.04 (+1.28%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-6.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BDSX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (44/100 Composite)

🔍 WHY BDSX SCORES 44/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+12/20 pts (27% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (25% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$26.02-9.1% Next Q

Q2 (-2Q)

Grade D$23.66-10.5% Next Q

Q3 (-1Q)

Grade D$21.18+16.7% Next Q

Current

Grade D$24.72-6.5% Hist 90D α

Trajectory: C- (52) → D (44)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BDSX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BDSX currently carries a cautious 44/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($26.46) and Max Pain ($25.96) forces dealer call-delta covering toward $33.57.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BDSX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “BDSX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 44%NO 56%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your BDSX Position Size: $10,000

Shares at $24.72: 404.5 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $18.06

$7,306

$-2,694 (-26.9%)

12M Consensus BaseTarget $23.16

$9,369

$-631 (-6.3%)

12M Bull Case BreakoutTarget $33.57

$13,580

+$3,580 (+35.8%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$24	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$32	69%	B
JP MorganUS Large-Cap Research	SELL	$21	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BDSX)

✓Walkthrough of BDSX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BDSX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +125.14%▲ ASCENDING CHANNEL

2026-10-30O $25.06H $25.06L $22.69C $24.72VOL 67.1K

RES: $38.85SUP: $20.16SMA50: $26.46SMA200: $18.67

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BDSX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BDSX Butterfly Map → + Track BDSX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +24.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BDSX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BDSX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BDSX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BDSX)

Health Care Rank #512 of 1016 ⚔️ TLSI vs BDSX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BDSX vs. TLSI, XGN, YDES, BNR)

Industry: Medical Specialities (41 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Biodesix Inc. (BDSX) ranks #512 by composite RQD confidence (44/100, grade D) and #539 by equity capitalization ($260.8M). Within this direct 5-issuer industry benchmark cohort, BDSX leads on earnings valuation at N/A trailing P/E, while YDES leads on capital efficiency and profitability with -20.0% ROIC and 28.1% gross margin. BDSX currently leads its immediate peer cohort in composite quantitative strength at 44/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BDSX ACTIVE Biodesix Inc.	D	44/100	—	—	-35.0%	+8.14%	$260.8M	Benchmark Subject
TLSI TriSalus Life Sciences Inc.	E	34/100	—	84.6%	-35.0%	-1.78%	$237.7M	/tlsi-vs-bdsx →
XGN Exagen Inc.	E	31/100	—	58.3%	-35.0%	+3.57%	$210.8M	/xgn-vs-bdsx →
YDES YD Bio Limited	D-	37/100	—	28.1%	-20.0%	-6.53%	$415.8M	/ydes-vs-bdsx →
BNR Burning Rock Biotech Limited	E	23/100	—	74.7%	-35.0%	-9.87%	$116.5M	/bnr-vs-bdsx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001439725

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Biodesix Inc. (BDSX) reported GAAP revenue of $88.5M (+24.1% vs. FY2024 revenue of $71.3M , and +80.3% cumulative change since FY2023) , GAAP net income of -$35.3M, operating cash flow of -$23.3M, and free cash flow of -$23.5M (+54.6% YoY). On the balance sheet, BDSX closed FY2025 with $87.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$88.5M	-$35.3M	-$23.3M	-$23.5M	$87.5M	—
FY2024 (FY)	2024-12-31	$71.3M	-$42.9M	-$48.6M	-$51.9M	$97.2M	—
FY2023 (FY)	2023-12-31	$49.1M	-$52.1M	-$22.9M	-$22.9M	—	—

3. BDSX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BDSX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Biodesix Inc. (NASDAQ: BDSX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $24.72 (+8.14% 1D, market cap $260.8M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, BDSX ranks #512 in composite RQD confidence.

How does BDSX compare to TLSI and XGN in the Health Care sector?

Within the Health Care sector (Medical Specialities), BDSX carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TLSI (TriSalus Life Sciences Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $237.7M) and XGN (Exagen Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $210.8M). Among the 5-stock peer group, BDSX leads on earnings multiple (N/A) while YDES leads on capital efficiency (-20.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BDSX?

Per BDSX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001439725), Biodesix Inc. generated $88.5M in revenue (+24.1% YoY), -$35.3M in net income, and -$23.5M in free cash flow against $87.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BDSX trading relative to its 50-day, 200-day, and 52-week technical levels?

BDSX last traded at $24.72 (+8.14% on volume of 70,260 shares), positioning the stock -6.58% below its 50-day simple moving average ($26.46) and +32.40% above its 200-day simple moving average ($18.67). Across its 52-week range of $5.26 to $31.97, BDSX sits at the 72.9% percentile with a 14-day RSI of 44.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($21.63 to $27.81).

BDSX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is BDSX's 12-month stock price target?

Biodesix Inc. (BDSX) carries a 12-month consensus base price target of $23.16 (-6.3% from $24.72), with a bull-case target of $33.57 and a bear-case floor of $18.06.

Is BDSX stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates BDSX D (Sell — SELL) with an RQD Confidence score of 44/100.

Direct Sub-Reports: BDSX RQD Cockpit BDSX 12M Forecast BDSX Earnings & Move BDSX Dividends & DRIP BDSX Insiders & 13F BDSX Whale Options BDSX Profit Sankey BDSX News & Why